Springleaf Therapeutics

SpringLeaf Therapeutics designs and develops advanced drug delivery systems, primarily focusing on a proprietary patch pump technology. This system facilitates the convenient, at-home administration of complex therapeutics that traditionally necessitate intravenous delivery in a clinical setting. The company’s approach integrates principles from materials science and medicine to create innovative modalities that improve patient access to critical treatments.

The company was founded in 2007 by Professor Michael Cima, Yet-Ming Chiang, and Richard Gyory. Cima and Chiang, both esteemed professors at the Massachusetts Institute of Technology, brought their deep expertise to address the pressing need for more accessible and patient-friendly drug administration methods. Their foundational insight centered on empowering patients to manage their treatments independently, thereby reducing the burden of frequent hospital visits for infusions.

SpringLeaf Therapeutics primarily serves patients who require regular administration of drugs that are typically given intravenously. The company's long-term vision is to elevate the overall quality of patient care and enhance the therapeutic experience by enabling safe, effective, and convenient self-administration of medicines. This forward-looking approach aims to redefine how patients receive and engage with their long-term treatment regimens.